C-7 | Left Ventricular Recovery After Impella 5.5 Placement in Patients With Cardiogenic Shock
نویسندگان
چکیده
Percutaneous mechanical circulatory support has traditionally been considered in patients with acute myocardial infarction (AMI), however, this technology is now being used for optimizing decompensated heart failure (ADHF). Widely accepted data on left ventricular recovery (LVR) focused the optimization of after durable assist devices (LVAD) but not described Impella. Current parameters defining LVR Impella 5.5 have yet to be established. We explore role and its effects by echocardiography ADHF. reviewed all who were listed transplant between October 2018 February 2022 supported 5.5. Patient extracted from electronic medical record. Baseline prior device placement post-device was performed at 14 days. A total 38 awaiting transplantation as temporary support. 35 these had pre- echocardiograms available review. The median age during 62 years (57 – 68), five females (14%). 51% Caucasian, 43% African American 6% Hispanic. Majority non-ischemic cardiomyopathy. duration 22 days (14 32) a baseline ejection fraction (LVEF) 19% (15 -24). end-diastolic dimension (LVEDD) 68 mm (62 71) LVEDD echocardiogram 60 (55 67), p = .006 two weeks. Average size decreased 1.5mm our cohort. Our demonstrate that can utilized safely non-AMI ADHF allows potential improvement LV size. Longer or earlier may allow increased potential. Further prospective studies larger populations addition predictive analysis provide higher fidelity understanding recovery.
منابع مشابه
[Initial experience with the Impella left ventricular assist device for postcardiotomy cardiogenic shock and unprotected left coronary artery angioplasty in patients with a low left ventricular ejection fraction].
Low-output syndrome is one of the leading causes of death following open-heart surgery or high-risk angioplasty. Ventricular assist devices have been used to treat patients who suffer from postoperative cardiogenic shock despite use of an intraaortic balloon pump and maximum inotropic support. The Impella pump (Impella Cardiosystems AG, Aachen, Germany) is a newly introduced left ventricular as...
متن کاملCombined pulmonary and left ventricular support with veno-pulmonary ECMO and impella 5.0 for cardiogenic shock after coronary surgery
BACKGROUND Mechanical circulatory support is a common practice nowadays in the management of patients after cardiogenic shock due to myocardial infarction. The single or combined use of one or more devices for mechanical support depends not only on the advantage or disadvantage of these devices but also on the timing of use of these devices before the development of multi organ failure. In our ...
متن کاملResponse to letter regarding article, “percutaneous left-ventricular support with the impella-2.5-assist device in acute cardiogenic shock results of the Impella-EUROSHOCK registry”.
BACKGROUND Acute cardiogenic shock after myocardial infarction is associated with high in-hospital mortality attributable to persisting low-cardiac output. The Impella-EUROSHOCK-registry evaluates the safety and efficacy of the Impella-2.5-percutaneous left-ventricular assist device in patients with cardiogenic shock after acute myocardial infarction. METHODS AND RESULTS This multicenter regi...
متن کاملCardiogenic shock: From ECMO to Impella and beyond.
For patients in cardiogenic shock, several devices can serve as a "bridge," ie, provide circulatory support and allow the patient to live long enough to recover or to receive a heart transplant or a long-term device. Options include an intra-aortic balloon pump, TandemHeart, Impella, extracorporeal membrane oxygenation (ECMO), and CentriMag. Which device to use depends on individual patient nee...
متن کاملManagement and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock
INTRODUCTION Cardiogenic shock refractory to standard therapy with inotropes and/or intra-aortic balloon pump is accompanied with an unacceptable high mortality. Percutaneous left ventricular assist devices may provide a survival benefit for these very sick patients. In this study, we describe our experience with the Impella 5.0 device used in the setting of refractory cardiogenic shock. METH...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Society for Cardiovascular Angiography & Interventions
سال: 2023
ISSN: ['2772-9303']
DOI: https://doi.org/10.1016/j.jscai.2023.100792